COVID-19 vaccine response in Neuromyelitis Optica Spectrum Disorder
Description
CONCLUSIONS: The study shows that NMOSD patients treated with rituximab may still be susceptible to severe COVID-19 infection even after both inactivated and mRNA vaccines.
